Which laboratory tests should be ordered to evaluate a woman with early menopause?

Laboratory Tests for Early Menopause Evaluation

For a woman presenting with suspected early menopause (premature ovarian insufficiency), you should order FSH and estradiol levels (repeated 4+ weeks apart if elevated), followed by karyotype, fragile-X premutation (FMR1) testing, anti-21-hydroxylase antibodies, and thyroid peroxidase antibodies. 1

Initial Diagnostic Hormonal Panel

The first-line laboratory assessment must include:

• hCG - to rule out pregnancy 1
• FSH - diagnostic threshold is >25 IU/L (not the older >40 IU/L cutoff) 1
• Estradiol - should be low, ruling out pre-ovulation peak or estrogen-secreting cyst 1
• Prolactin - to exclude hyperprolactinemia as alternative diagnosis 1

Critical timing consideration: If FSH is elevated (>25 IU/L) and estradiol is low, repeat these tests at least 4 weeks later to confirm the diagnosis, as POI diagnosis requires two elevated FSH measurements 1. This is essential because FSH can fluctuate, and a single measurement may capture a pre-ovulatory surge.

Important caveat: Women on combined hormonal contraception or macro-progestins will have falsely suppressed FSH levels. You must discontinue these medications and wait at least 3 months before retesting 1.

Etiological Work-Up

Once POI is confirmed hormonally, proceed with:

Genetic Testing (Mandatory)

• Karyotype - perform in all women with non-iatrogenic POI to detect chromosomal abnormalities including Turner syndrome mosaicism and Y chromosome material 2, 1
• Fragile-X premutation (FMR1) testing - indicated in all POI cases, with genetic counseling beforehand given implications for family members 2, 1

Critical action: If Y chromosomal material is detected, gonadectomy is mandatory due to malignancy risk 2.

Autoimmune Screening (Strongly Recommended)

• Anti-21-hydroxylase antibodies (21OH-Ab) or adrenocortical antibodies (ACA) - screen for subclinical Addison's disease 2, 1
• Thyroid peroxidase antibodies (TPO-Ab) - assess for autoimmune thyroid disease 2, 1

Follow-up protocol:

• If 21OH-Ab/ACA positive → refer to endocrinology immediately for adrenal function testing to rule out Addison's disease 2
• If TPO-Ab positive → measure TSH annually 2
• If both antibodies are negative initially, do not repeat unless new symptoms develop 2

Optional/Adjunctive Tests

• AMH (anti-Müllerian hormone) - reflects follicular reserve but not required for diagnosis; typically collapsed in POI 1
• TSH - if TPO-Ab positive or clinical suspicion of thyroid dysfunction 2

Tests NOT Routinely Indicated

• Diabetes screening - insufficient evidence to recommend routinely 2
• Infection screening - no indication 2
• Autosomal genetic panels - only if specific syndrome suspected (e.g., BPES) 2
• Bone mineral density - important for management but not diagnostic 1

Key Pitfalls to Avoid

1. Don't rely on a single FSH measurement - the 4-week repeat is mandatory for diagnosis
2. Don't test FSH while patient is on hormonal contraception - wait 3 months after discontinuation
3. Don't skip the karyotype - it's mandatory even when cause seems obvious
4. Don't forget genetic counseling before fragile-X testing - has implications for family planning and relatives
5. Don't ignore positive autoimmune markers - 21OH-Ab positivity requires urgent endocrine referral as Addison's disease can be life-threatening

The FSH threshold has been lowered from historical values because autoimmune POI often presents with FSH levels between 25-35 IU/L rather than the higher levels (37+ IU/L) seen in idiopathic cases 1. This more sensitive threshold prevents missed diagnoses in autoimmune etiologies.